Kevin James Metcalf

Kevin James Metcalf

Auto-generated profile, based on publicly available information

Kevin James Metcalf

Department of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, Wisconsin, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJuliane Winkler
Juliane Winkler
AAAbisola Abisoye-Ogunniyan
Abisola Abisoye-Ogunniyan
KMKevin J. Metcalf
Kevin J. Metcalf
ZWZena Werb
Zena Werb
Tissues are dynamically shaped by bidirectional communication between resident cells and the extracellular matrix (ECM) through cell-matrix interactions and ECM remodelling. Tumours leverage ECM remodelling to create a microenvironment that promotes tumourigenesis and metastasis. In this review, we focus on how tumour and tumour-associated stromal cells deposit, biochemically and biophysically modify, and degrade tumour-associated ECM. These tumour-driven changes support tumour growth, increase migration of tumour cells, and remodel the ECM in distant organs to allow for metastatic progression. A better understanding of the underlying mechanisms of tumourigenic ECM remodelling is crucial for developing therapeutic treatments for patients.

15 September 2014 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
MBMichael L. Burns
Michael L. Burns
TMThomas M. Malott
Thomas M. Malott
KMKevin J. Metcalf
Kevin J. Metcalf
BHBenjamin J. Hackel
Benjamin J. Hackel
JCJonah R. Chan
Jonah R. Chan
ESEric Shusta
Eric Shusta
Brain-derived neurotrophic factor (BDNF) plays an important role in nervous system function and has therapeutic potential. Microbial production of BDNF has resulted in a low-fidelity protein product, often in the form of large, insoluble aggregates incapable of binding to cognate TrkB or p75 receptors. In this study, employing Saccharomyces cerevisiae display and secretion systems, it was found that BDNF was poorly expressed and partially inactive on the yeast surface and that BDNF was secreted at low levels in the form of disulfide-bonded aggregates. Thus, for the purpose of increasing the compatibility of yeast as an expression host for BDNF, directed-evolution approaches were employed to improve BDNF folding and expression levels. Yeast surface display was combined with two rounds of directed evolution employing random mutagenesis and shuffling to identify BDNF mutants that had 5-fold improvements in expression, 4-fold increases in specific TrkB binding activity, and restored p75 binding activity, both as displayed proteins and as secreted proteins. Secreted BDNF mutants were found largely in the form of soluble homodimers that could stimulate TrkB phosphorylation in transfected PC12 cells. Site-directed mutagenesis studies indicated that a particularly important mutational class involved the introduction of cysteines proximal to the native cysteines that participate in the BDNF cysteine knot architecture. Taken together, these findings show that yeast is now a viable alternative for both the production and the engineering of BDNF.

15 March 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
KMKevin J. Metcalf
Kevin J. Metcalf
AAAlaa Alazzeh
Alaa Alazzeh
ZWZena Werb
Zena Werb
VWValerie M Weaver
Valerie M Weaver
Treatment resistance leads to cancer patient mortality. Therapeutic approaches that employ synthetic lethality to target mutational vulnerabilities in key tumor cell signaling pathways have proven effective in overcoming therapeutic resistance in some cancers. Yet, tumors are organs composed of malignant cells residing within a cellular and noncellular stroma. Tumor evolution and resistance to anticancer treatment are mediated through a dynamic and reciprocal dialogue with the tumor microenvironment (TME). Accordingly, expanding tumor cell synthetic lethality to encompass contextual synthetic lethality has the potential to eradicate tumors by targeting critical TME circuits that promote tumor progression and therapeutic resistance. In this Review, we summarize current knowledge about the TME and discuss its role in treatment. We outline the concept of tumor cell–specific synthetic lethality and describe therapeutic approaches to expand this paradigm to leverage TME synthetic lethality to improve cancer therapy.

20 May 2015 in Biotechnology and Bioengineering
Verified
Journal Article
Closed access
PDF file
AAAnum Azam
Anum Azam
CLCheng Li
Cheng Li
KMKevin J. Metcalf
Kevin J. Metcalf
DTDanielle Tullman‐Ercek
Danielle Tullman‐Ercek

1 October 2014 in Applied and Environmental Microbiology
Verified
Journal Article
Open access
PDF file
KMKevin J. Metcalf
Kevin J. Metcalf
CFCasey Finnerty
Casey Finnerty
AAAnum Azam
Anum Azam
EVElias Valdivia
Elias Valdivia
DTDanielle Tullman-Ercek
Danielle Tullman-Ercek
The type III secretion system (T3SS) encoded at the Salmonella pathogenicity island 1 (SPI-1) locus secretes protein directly from the cytosol to the culture media in a concerted, one-step process, bypassing the periplasm. While this approach is attractive for heterologous protein production, product titers are too low for many applications. In addition, the expression of the SPI-1 gene cluster is subject to native regulation, which requires culturing conditions that are not ideal for high-density growth. We used transcriptional control to increase the amount of protein that is secreted into the extracellular space by the T3SS of Salmonella enterica . The controlled expression of the gene encoding SPI-1 transcription factor HilA circumvents the requirement of endogenous induction conditions and allows for synthetic induction of the secretion system. This strategy increases the number of cells that express SPI-1 genes, as measured by promoter activity. In addition, protein secretion titer is sensitive to the time of addition and the concentration of inducer for the protein to be secreted and SPI-1 gene cluster. Overexpression of hilA increases secreted protein titer by >10-fold and enables recovery of up to 28 ± 9 mg/liter of secreted protein from an 8-h culture. We also demonstrate that the protein beta-lactamase is able to adopt an active conformation after secretion, and the increase in secreted titer from hilA overexpression also correlates to increased enzyme activity in the culture supernatant.

10 December 2020 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
KMKevin J. Metcalf
Kevin J. Metcalf
BKBlaise Russel Kimmel
Blaise Russel Kimmel
DSDaniel J. Sykora
Daniel J. Sykora
JMJustin A. Modica
Justin A. Modica
KPKelly A. Parker
Kelly A. Parker
MMMilan Mrksich
Milan Mrksich